Last updated on October 2017

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema


Brief description of study

Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively. The main objectives of this observational cohort field study are to evaluate effectiveness of intravitreal aflibercept and to describe follow-up as well as treatment patterns in anti vascular endothelial growth factor (anti-VEGF) treatment naïve patients with DMO in routine clinical practice in the United Kingdom.

Clinical Study Identifier: NCT02850263

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Bayer Clinical Trials Contact

Many Locations, United Kingdom
  Connect »